BioSpace News Archive

EsoCap AG is supporting the first European EoE day to be launched on 22 May 2022 initiated by EUREOS and AEDESEO, the Spanish association of EoE patients.

Scientists from the University of Birmingham have shown an existing drug may reduce damage after spinal cord injury, by blocking the inflammatory response in the spinal cord.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference now scheduled for Tuesday, May 24 at 9:00 a.m. ET.

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the X-Twist TM Knotless Fixation System.

Nutriband Inc., is pleased to announce that it has been invited to present at the Emerging Growth Conference on May 25, 2022.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral presentation at the 5 th Global NASH Congress on May 26-27, 2022, in London, UK.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference taking place next week.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate company Phoenix Tissue Repair announced data from the Phase 2 trial of PTR-01, an intravenously-administered recombinant collagen 7 (rC7) protein replacement therapy, in patients with recessive dystrophic epidermolysis bullosa (RDEB).

BiomX Inc. announced the publication of a scientific paper titled “Exodus: Sequencing-based Pipeline for Quantification of Pooled Variants” in the journal, Bioinformatics.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Upstaza™ (eladocagene exuparvovec; PTC-AADC) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).